02179 瑞科生物 - B
RECBIO-B
RECBIO-B
| Listing Date | 2022/03/31 |
| Listing Price | 24.800 |
Quote
Subscription Result
- Subscription Rate10.65x
- Guarantee One Lot Size12 lot
- One Lot Success Rate9.28%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Jiangsu Recbio Technology founded in 2012, it is a vaccine company dedicated to the research, development and commercialization of subunit vaccines. It primarily focuses on the R&D of HPV vaccine candidates.
The Group has established a vaccine portfolio consisting of 12 vaccine candidates, including its Core Product, REC603, a recombinant HPV 9-valent vaccine to prevent cervical cancer which is currently under phase III clinical trial.
In addition to REC603, the Group is also developing two recombinant HPV bivalent vaccine candidates, namely REC601 and REC602, targeting HPV 16/18 and HPV 6/11, respectively.
The Group is currently developing two COVID-19 vaccines. It was currently finalizing data analysis and clinical trial report in March 2022.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 500 |
GLOBAL OFFERING
| No. of Offer Shares | 30.85M H shares |
| No. of International Offer Shares | 27.77M H shares |
| No. of HK Offer Shares | 3.09M H shares |
| Offer Price | $24.80 |
| Stock Code | 2179 |
| Sponsor(s) | Morgan Stanley Asia Limited, CMB International Capital Limited, CLSA Capital Markets Limited |
| Underwriter(s) | -- |
TIME TABLE
| Application Period | Mar 21 (Mon) - noon, Mar 24 (Thu) |
| Price Determination Date | -- |
| Result Announcement Date | On or before Mar 30 (Wed) |
| Result Announcement Date | On or before Mar 30 (Wed) |
| Dealings in Shares commence on | Mar 31, 2022. (Thu) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $24.80 |
| Capitalization | 11.88B |
| NAV / share ($) | $6.00 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 24.8, the net proceeds raised would be HKD 672.40M, of which |
| 47.3% : research and development, manufacturing and commercialization of HPV vaccine pipeline |
| 17.7% : for COVID-19 vaccine candidate ReCOV |
| 21.1% : for remaining vaccine candidates |
| 6.7% : strengthen R&D capabilities |
| 7.2% : working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).